Mild TSH Elevation in a Preterm Infant: Treat Now or Repeat?
A preterm infant born at 34 weeks is now 3 weeks old. Newborn screening at 72 hours showed TSH 25 mIU/L; repeat at 2 weeks is TSH 18 mIU/L and free T4 0.8 ng/dL (low for age). The infant is feeding well, has normal tone, and no goiter. Mother has Hashimoto thyroiditis and takes levothyroxine; maternal TSH is 2.5 mIU/L. The infant was asymptomatic in the nursery and was discharged without thyroid medication. The pediatrician is unsure whether this is transient hypothyroxinemia of prematurity, maternal antibody effect, or true congenital hypothyroidism, and whether treatment can wait until 6 weeks.
1. Interpret the thyroid tests in this preterm infant. Which confounders matter most?
Read the worked answer
The combination of a persistently elevated TSH (18 mIU/L) and a low free T4 for age is abnormal and cannot be dismissed as asymptomatic transient hypothyroxinemia of prematurity. In preterm infants, free T4 is normally lower than in term infants, but a TSH above the age-specific limit with low free T4 suggests primary hypothyroidism. Maternal Hashimoto disease can cause transient hypothyroidism through transplacental TSH-receptor-blocking antibodies, but this is less likely when the maternal TSH is normal and the infant’s TSH is clearly elevated. Preterm infants can have a blunted TSH surge, so a high TSH is especially concerning. Illness and sampling timing can affect results, but the repeat value confirms the pattern. The most important confounder is age-specific interpretation: free T4 and TSH thresholds differ in preterm infants, and treatment should not be delayed while waiting for a 6-week repeat.
2. Should treatment start now? If so, what dose and monitoring plan would you use?
Read the worked answer
Yes. I would start levothyroxine now rather than wait. Congenital hypothyroidism is a time-sensitive neurodevelopmental condition, and the confirmatory repeat already shows low free T4 with elevated TSH. A typical starting dose is 10–15 mcg/kg/day, individualized to the infant’s weight and clinical status; preterm infants may need lower initial dosing with careful titration. I would recheck free T4 and TSH in 2–4 weeks, then every 1–2 months in infancy, aiming for free T4 in the upper half of the age-specific range and a normal TSH. I would counsel about giving the dose consistently, not mixing it with feeds that impair absorption, and watching for over-treatment such as tachycardia, poor feeding, or irritability. I would also notify the newborn screening program and arrange pediatric endocrine follow-up.
3. How would you distinguish transient from permanent congenital hypothyroidism later?
Read the worked answer
The later distinction depends on the cause and the course. If imaging shows thyroid dysgenesis, permanent hypothyroidism is essentially certain and lifelong treatment is needed. If the gland is normal and there is no known dyshormonogenesis, a trial off levothyroxine can be considered around age 3 years, after the period of rapid brain development, with close monitoring of free T4 and TSH. A rise in TSH after stopping confirms permanent hypothyroidism. Transient causes include maternal blocking antibodies, iodine exposure, and transient hypothyroxinemia of prematurity; these usually resolve. In this infant, the persistently elevated TSH makes transient hypothyroxinemia less likely, but maternal antibody-mediated transient hypothyroidism remains possible. The trial should not be done before age 3 without endocrine guidance, and growth and development must be monitored throughout.